Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 435 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lymph Clear all
Terminated Phase 1 Interventional

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

NCT00800150
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy, tomotherapy, total marrow irradiation, total nodal irradiation
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Not applicable Interventional Results available

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

NCT00070317
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage I Cervical Cancer
Interventions
Isosulfan Blue, Lymph Node Mapping, Lymphangiography, Methylene Blue, Radionuclide Imaging, Sentinel Lymph Node Biopsy, Technetium Tc-99m Sulfur Colloid, Therapeutic Conventional Surgery
Drug · Procedure · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Not yet recruiting No phase listed Observational

SLN Mapping and ICG Dye for Vulvar Cancer

NCT06035068
View directory record Official record
Conditions
Vulva Cancer
Interventions
Indocyanine green
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 4 Interventional

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

NCT00002179
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix

NCT01600040
View directory record Official record
Conditions
Uterine Cancer, Cervical Cancer
Interventions
Proton radiation therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Active, not recruiting No phase listed Observational

The OPBC-07/microNAC Study

NCT06529302
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

NCT00433511
View directory record Official record
Conditions
Breast Adenocarcinoma
Interventions
Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4,994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
840
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Results available

Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine

NCT05691530
View directory record Official record
Conditions
Response To Dengue Exposure
Interventions
rDEN3Δ30/31-7164
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 59 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effect of Intrawound Vancomycin Powder on Surgical Site Infection in Inguinal Lymph Node Dissection

NCT05625373
View directory record Official record
Conditions
Postoperative Complications
Interventions
Vancomycin
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Early Phase 1 Interventional

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

NCT04051502
View directory record Official record
Conditions
Ovarian Cancer, Adnexal Mass
Interventions
Method 1: Indocyanine green dye, Method 2: Indocyanine green dye, Method 3: Indocyanine green dye
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer

NCT06677112
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Selective surgical staging, REFLEX
Procedure
Lead sponsor
Rachel Miller
Other
Eligibility
18 Years and older · Female only
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

NCT06593665
View directory record Official record
Conditions
Testicular Cancer
Interventions
Inrathecal Morphine, Intravenous Methadone
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Not yet recruiting Phase 1 Interventional

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer

NCT05038098
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Gastrectomy, Indocyanine Green, Iron Conjugated Polymers in Saline Suspension
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Withdrawn Not applicable Interventional

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

NCT01983371
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Scott Potenta, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients

NCT00507611
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Sentinel node mapping
Procedure
Lead sponsor
Stephen Povoski
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 19, 2026, 4:21 AM EDT
Completed No phase listed Observational

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

NCT01276899
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsies, Needle core biopsies of metastatic lesion
Procedure
Lead sponsor
Jewish General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG

NCT02068820
View directory record Official record
Conditions
Endometrial Cancer
Interventions
ISB dye and standard white light imaging, ICG dye and FireFly fluorescence imaging
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 19, 2026, 4:21 AM EDT
Completed No phase listed Observational

Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer

NCT02834988
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 19, 2026, 4:21 AM EDT
Completed No phase listed Observational

Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer

NCT05255393
View directory record Official record
Conditions
Cervical Cancer, Vulvar Cancer
Interventions
Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

NIR-Guided Sentinel Lymph Node Mapping in Melanoma

NCT01121718
View directory record Official record
Conditions
Melanoma
Interventions
ICG Intervention
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated No phase listed Observational

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

NCT00918008
View directory record Official record
Conditions
Bladder Cancer
Interventions
Blood draw
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

NCT00074490
View directory record Official record
Conditions
Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions
Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI)
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Years to 90 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

NCT01460875
View directory record Official record
Conditions
Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
recombinant interferon alfa-2b, laboratory biomarker analysis
Biological · Other
Lead sponsor
William Carson
Other
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

NCT05646316
View directory record Official record
Conditions
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy, Indocyanine Green Solution, Minimally Invasive Surgery, Pelvic Lymphadenectomy, Questionnaire Administration, Sentinel Lymph Node Mapping
Procedure · Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
55
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Deerfield Beach, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 19, 2026, 4:21 AM EDT